posit finch data focu file
bottom line report number glpg better
expect bottom line quarterli number less focu
investor posit readout filgotinib finch studi
rheumatoid arthriti compani state expect pre-
nda meet fda happen next month
focus data fda may requir on-going male
reproduct safeti studi manta file model current
assum ww launch earlier us launch fda
requir full manta data would repres upsid continu see
filgotinib best-in-class potenti although file timelin go
long way determin outlook competit ra market also like
broad filgotinib develop program beyond ra along
promis asset glpg pipelin includ idiopath pulmonari
fibrosi osteoarthr atop dermat give sharehold multipl
way win see phase data filgotinib sjgren
syndrom cutan lupu along top-line data earlier
program see top-line data
subcutan bridg studi phase data atop dermat
push back order expand patient pool
lower rev expens rev
due lower recognit mileston oper expens
lower primarili due lower spend
burn guidanc unchang compani maintain
cash burn guidanc compani includ littl
revenu mileston number expect advanc number
molecul later stage studi includ second toledo compound
maintain outperform rate target price glpg share
revis ep
risk includ delay/ failur pipelin asset
valuat metric
number share
price month
amsterdam exchang
close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
galapago clinic stage biotech compani focus
develop novel treatment rheumatoid arthriti inflammatori
bowel diseas idiopath pulmonari fibrosi atop dermat
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base po filgotinib
better-than-expect data pipelin drug
blue sky valuat base
dcf driven wacc discount cash flow
termin growth rate thereaft
grey sky valuat base po filgotinib
worse-than-expect data pipelin drug
grey sky valuat base
dcf driven wacc discount cash flow
termin growth rate thereaft
amsterdam exchang close
sale
net profit/ loss continu oper
net incom discontinu oper
weight average share calcul dilut ep
gross margin ex-royalti incom
compani mention price
